Rodrigo Nalio Ramos

Rodrigo Nalio Ramos

Auto-generated profile, based on publicly available information

Rodrigo Nalio Ramos

INSERM U932, PSL University, Institut Curie Research Center, Paris, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Cell
Verified
Journal Article
Closed access
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
YMYoann Missolo-Koussou
Yoann Missolo-Koussou
YGYohan Gerber-Ferder
Yohan Gerber-Ferder
CBChristian Bromley
Christian Bromley
MBMattia Bugatti
Mattia Bugatti
JHJulie Helft
Julie Helft

29 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NNNicolas Gonzalo Núñez
Nicolas Gonzalo Núñez
JBJimena Tosello Boari
Jimena Tosello Boari
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
WRWilfrid Richer
Wilfrid Richer
NCNicolas Cagnard
Nicolas Cagnard
EPEliane Piaggio
Eliane Piaggio
Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, and that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.

7 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GGGabriela Rapozo Guimarães
Gabriela Rapozo Guimarães
GMGiovanna Resk Maklouf
Giovanna Resk Maklouf
CTCristiane Esteves Teixeira
Cristiane Esteves Teixeira
LSLeandro de Oliveira Santos
Leandro de Oliveira Santos
NTNayara Tessarollo
Nayara Tessarollo
MBMariana Boroni
Mariana Boroni
Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations. Using deconvolution approaches, we identify five subpopulations as independent prognostic markers, including states co-expressing TREM2 and PD-1, and FOLR2 and PDL-2. Additionally, TREM2 alone does not reliably predict cancer prognosis, as other TREM2+ macrophages show varied associations with prognosis depending on local cues. Validation in independent cohorts confirms that FOLR2-expressing macrophages correlate with poor clinical outcomes in ovarian and triple-negative breast cancers. This comprehensive MDC atlas offers valuable insights and a foundation for futher analyses, advancing strategies for treating solid cancers.

27 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LBLuciana Rodrigues Carvalho Barros
Luciana Rodrigues Carvalho Barros
SCSamuel Campanelli Freitas Couto
Samuel Campanelli Freitas Couto
DSDaniela da Silva Santurio
Daniela da Silva Santurio
EPEmanuelle Paixão
Emanuelle Paixão
FCFernanda Cardoso
Fernanda Cardoso
VRVanderson Geraldo Rocha
Vanderson Geraldo Rocha
In this systematic review, we foresee what could be the approved scenario in the next few years for CAR-T cell therapies directed against hematological and solid tumor malignancies. China and the USA are the leading regions in numbers of clinical studies involving CAR-T. Hematological antigens CD19 and BCMA are the most targeted, followed by mesothelin, GPC3, CEA, MUC1, HER2, and EGFR for solid tumors. Most CAR constructs are second-generation, although third and fourth generations are being largely explored. Moreover, the benefit of combining CAR-T treatment with immune checkpoint inhibitors and other drugs is also being assessed. Data regarding product formulation and administration, such as cell phenotype, transfection technique, and cell dosage, are scarce and could not be retrieved. Better tracking of trials’ status and results on the ClinicalTrials.gov database should aid in a more concise and general view of the ongoing clinical trials involving CAR-T cell therapy.

23 November 2012 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
TGThais Helena Gasparoto
Thais Helena Gasparoto
COCarine Ervolino de Oliveira
Carine Ervolino de Oliveira
LFLuisa Thomazini de Freitas
Luisa Thomazini de Freitas
CPClaudia Ramos Pinheiro
Claudia Ramos Pinheiro
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
ACAna Paula Campanelli
Ana Paula Campanelli
Background: Squamous cell carcinoma (SCC) is one of the most common human cancers worldwide. In SCC, tumour development is accompanied by an immune response that leads to massive tumour infiltration by inflammatory cells, and consequently, local and systemic production of cytokines, chemokines and other mediators. Studies in both humans and animal models indicate that imbalances in these inflammatory mediators are associated with cancer development. Methods: We used a multistage model of SCC to examine the involvement of elastase (ELA), myeloperoxidase (MPO), nitric oxide (NO), cytokines (IL-6, IL-10, IL-13, IL-17, TGF-β and TNF-α), and neutrophils and macrophages in tumour development. ELA and MPO activity and NO, IL-10, IL −17, TNF-α and TGF-β levels were increased in the precancerous microenvironment. Results: ELA and MPO activity and NO, IL-10, IL −17, TNF-α and TGF-β levels were increased in the precancerous microenvironment. Significantly higher levels of IL-6 and lower levels of IL-10 were detected at 4 weeks following 7,12-Dimethylbenz(a)anthracene (DMBA) treatment. Similar levels of IL-13 were detected in the precancerous microenvironment compared with control tissue. We identified significant increases in the number of GR-1+ neutrophils and F4/80+/GR-1- infiltrating cells in tissues at 4 and 8 weeks following treatment and a higher percentage of tumour-associated macrophages (TAM) expressing both GR-1 and F4/80, an activated phenotype, at 16 weeks. We found a significant correlation between levels of IL-10, IL-17, ELA, and activated TAMs and the lesions. Additionally, neutrophil infiltrate was positively correlated with MPO and NO levels in the lesions. Conclusion: Our results indicate an imbalance of inflammatory mediators in precancerous SCC caused by neutrophils and macrophages and culminating in pro-tumour local tissue alterations.

10 December 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
RRRodrigo Nalio Ramos
Rodrigo Nalio Ramos
SCSamuel Campanelli Freitas Couto
Samuel Campanelli Freitas Couto
TOTheo Gremen M. Oliveira
Theo Gremen M. Oliveira
PKPaulo Klinger
Paulo Klinger
TBTarcio Teodoro Braga
Tarcio Teodoro Braga
VRVanderson Geraldo Rocha
Vanderson Geraldo Rocha
Chimeric antigen receptor (CAR) engineering for T cells and natural killer cells (NK) are now under clinical evaluation for the treatment of hematologic cancers. Although encouraging clinical results have been reported for hematologic diseases, pre-clinical studies in solid tumors have failed to prove the same effectiveness. Thus, there is a growing interest of the scientific community to find other immune cell candidate to express CAR for the treatment of solid tumors and other diseases. Mononuclear phagocytes may be the most adapted group of cells with potential to overcome the dense barrier imposed by solid tumors. In addition, intrinsic features of these cells, such as migration, phagocytic capability, release of soluble factors and adaptive immunity activation, could be further explored along with gene therapy approaches. Here, we discuss the elements that constitute the tumor microenvironment, the features and advantages of these cell subtypes and the latest studies using CAR-myeloid immune cells in solid tumor models.